Satisfai Health Purchases Assets of Docbot, Inc.

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.


Satisfai Health, Inc.


Solidifies Satisfai as one of the leading technology companies globally in artificial intelligence for gastroenterology

Vancouver, British Columbia, Canada - TheNewswire - 21 November 2022 – Satisfai Health, Inc (“Satisfai”) today announces its strategic acquisition of Docbot, Inc’s portfolio of Intellectual Property and Assets which is complementary and accretive to Satisfai’s products and technology stack, focused in the field of artificial intelligence (AI) as applied to gastrointestinal endoscopy. In addition, key Docbot technical employees have been transferred to Satisfai.

“For years, we have held the Docbot team in very high regard as among the world leading experts in the field of AI in gastroenterology,” said Dr. Michael Byrne, CEO and founder of Satisfai Health, Clinical Professor of Medicine, and gastroenterologist in Vancouver. “This acquisition will allow Satisfai to expand its team of machine learning and allied technical experts with domain experience in gastroenterology and AI, as well as add IP and AI tools that will accelerate our existing pipeline of products and services, solidifying Satisfai’s leadership position in this field. I am personally very grateful to the Docbot CEO, Andrew Ritter, and the founding physicians, Dr. William Karnes and Dr. Jason Samarasena, for trusting us to further develop and commercialize their patented technologies after so many years of dedication and hard work.”

Through this acquisition, Satisfai plans to accelerate many aspects of its product roadmap, such as management of colon polyps, upper GI cancers, and inflammatory bowel disease, as well as improving quality assurance and bringing automated documentation of endoscopic procedures to improve workflow in clinical practice.

On behalf of the Board of Satisfai Health Inc.

"Dr Michael F. Byrne"

Chairman & CEO


About Satisfai Health 

Satisfai is a leading medical solutions provider specializing in AI applications applied to large addressable markets in gastroenterology. Satisfai’s solutions deliver real-time medical imagery analysis, providing clinicians with decision support intelligence that dramatically improves patient outcomes. Satisfai is supported by a highly respected board of medical clinicians and key opinion leaders who operate at the top of their fields in the many areas of gastroenterology. Satisfai enjoys a strong voice on academic panels and leading GI societies, and direct access to prominent industry players seeking to adopt new AI technologies in gastroenterology. For more information, visit

About Docbot 

Docbot, Inc. develops leading artificial intelligence (AI)-driven healthcare applications in the field of gastroenterology. Its flagship product, UltivisionAI, is a real-time AI image analysis platform for reliable clinical outcomes, practice management workflow efficiencies and data-driven analytics to support the entire practice of GI, including therapeutic areas of colon cancer, esophageal cancer, inflammatory bowel disease screening and diagnosis.

Satisfai Media Contact

Andrew Stibbs

[email protected]


Copyright (c) 2022 TheNewswire - All rights reserved.